ECSP11011219A - NEW POLYMODIC FORMS OF DIHYDROGEN-PHOSPHATE 6- (1-METHYL-1H-PIRAZOL-4-IL) -2- {3- [5- (2-MORFOLIN-4-IL-ETOXI) -PIRIMIDIN-2-IL] -BENCIL} -2H-PIRIDAZIN-3-ONA AND PROCESSES FOR PREPARATION. - Google Patents

NEW POLYMODIC FORMS OF DIHYDROGEN-PHOSPHATE 6- (1-METHYL-1H-PIRAZOL-4-IL) -2- {3- [5- (2-MORFOLIN-4-IL-ETOXI) -PIRIMIDIN-2-IL] -BENCIL} -2H-PIRIDAZIN-3-ONA AND PROCESSES FOR PREPARATION.

Info

Publication number
ECSP11011219A
ECSP11011219A EC2011011219A ECSP11011219A ECSP11011219A EC SP11011219 A ECSP11011219 A EC SP11011219A EC 2011011219 A EC2011011219 A EC 2011011219A EC SP11011219 A ECSP11011219 A EC SP11011219A EC SP11011219 A ECSP11011219 A EC SP11011219A
Authority
EC
Ecuador
Prior art keywords
methyl
processes
dihydrogen
phosphate
polymodic
Prior art date
Application number
EC2011011219A
Other languages
Spanish (es)
Inventor
Dieter Dorsch
Christoph Saal
Frank Stieber
Axel Becker
Clemens Kuehn
Eva Kriegbaum
Cristina Donini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41609799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011219(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP11011219A publication Critical patent/ECSP11011219A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a dihidrógeno-fosfato de 6-(1-metil-1H-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2H-piridazin-3-ona, sus solvatos y modificaciones cristalinas. La presente invención también se refiere a procesos de preparación de estas modificaciones cristalinas, así como a su uso en el tratamiento y/o la prevención de condiciones fisiológicas y/o patofisiológicas que son causadas, mediadas y/o propagadas por la inhibición, regulación y/o modulación de la transducción de señales de quinasas, en particular por la inhibición de tirosina quinasas, por ejemplo, condiciones patofisiológicas como el cáncer.The present invention relates to 6- (1-methyl-1H-pyrazol-4-yl) -2- {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2- dihydrogen phosphate il] -benzyl} -2H-pyridazin-3-one, its solvates and crystalline modifications. The present invention also relates to processes for preparing these crystalline modifications, as well as their use in the treatment and / or prevention of physiological and / or pathophysiological conditions that are caused, mediated and / or propagated by inhibition, regulation and / or modulation of kinase signal transduction, in particular by the inhibition of tyrosine kinases, for example, pathophysiological conditions such as cancer.

EC2011011219A 2008-12-22 2011-07-21 NEW POLYMODIC FORMS OF DIHYDROGEN-PHOSPHATE 6- (1-METHYL-1H-PIRAZOL-4-IL) -2- {3- [5- (2-MORFOLIN-4-IL-ETOXI) -PIRIMIDIN-2-IL] -BENCIL} -2H-PIRIDAZIN-3-ONA AND PROCESSES FOR PREPARATION. ECSP11011219A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08022253 2008-12-22

Publications (1)

Publication Number Publication Date
ECSP11011219A true ECSP11011219A (en) 2011-12-30

Family

ID=41609799

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011219A ECSP11011219A (en) 2008-12-22 2011-07-21 NEW POLYMODIC FORMS OF DIHYDROGEN-PHOSPHATE 6- (1-METHYL-1H-PIRAZOL-4-IL) -2- {3- [5- (2-MORFOLIN-4-IL-ETOXI) -PIRIMIDIN-2-IL] -BENCIL} -2H-PIRIDAZIN-3-ONA AND PROCESSES FOR PREPARATION.

Country Status (31)

Country Link
US (1) US8586599B2 (en)
EP (1) EP2361250B1 (en)
JP (2) JP5690741B2 (en)
KR (1) KR101663335B1 (en)
CN (1) CN102264729B (en)
AR (1) AR074686A1 (en)
AU (1) AU2009331990B2 (en)
BR (1) BRPI0923480B8 (en)
CA (1) CA2748218C (en)
CL (1) CL2011001278A1 (en)
CO (1) CO6331435A2 (en)
CY (1) CY1114659T1 (en)
DK (1) DK2361250T3 (en)
EA (1) EA019320B1 (en)
EC (1) ECSP11011219A (en)
ES (1) ES2434247T3 (en)
HR (1) HRP20130993T1 (en)
IL (1) IL213647A (en)
MX (1) MX2011006682A (en)
MY (1) MY160526A (en)
NZ (1) NZ594172A (en)
PE (1) PE20120016A1 (en)
PL (1) PL2361250T3 (en)
PT (1) PT2361250E (en)
SG (1) SG172128A1 (en)
SI (1) SI2361250T1 (en)
SM (1) SMT201300133B (en)
TW (1) TWI448463B (en)
UA (1) UA103646C2 (en)
WO (1) WO2010072295A1 (en)
ZA (1) ZA201105394B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062826A1 (en) * 2008-12-23 2010-07-01 Merck Patent Gmbh pyridazinone derivatives
KR20180092096A (en) 2017-02-08 2018-08-17 에이비온 주식회사 Novel Polymorphic Forms of Triazolopyrazine Derivatives and Processes of Manufacturing Thereof
US11180480B2 (en) 2017-10-17 2021-11-23 Sensorion Synthesis of 4-aminopyrimidine compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19604388A1 (en) 1996-02-07 1997-08-14 Merck Patent Gmbh New aryl-alkyl diazinone derivatives
JPH10259176A (en) 1997-03-17 1998-09-29 Japan Tobacco Inc New amide derivative having vascularization inhibiting action and its use
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
US20040259863A1 (en) 2001-10-31 2004-12-23 Hans-Michael Eggenweiler Type 4 phosphodiesterase inhibitors and uses thereof
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
JP2007516180A (en) 2003-07-02 2007-06-21 スゲン，インコーポレイティド Arylmethyltriazolo and imidazopyrazines as c-Met inhibitors
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
KR20080080584A (en) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of c-methet and uses thereof
DE102005057924A1 (en) 2005-12-05 2007-06-06 Merck Patent Gmbh pyridazinone derivatives
HRP20170103T1 (en) 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopyridazines as tyrosine kinase modulators
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (en) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazole pyrazine derivatives.
PE20080403A1 (en) 2006-07-14 2008-04-25 Amgen Inc FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (en) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (en) 2007-07-12 2009-04-02 Merck Patent Gmbh pyridazinone derivatives
JP2011500629A (en) 2007-10-16 2011-01-06 ノバルティス アーゲー Substituted piperazines and piperidines as modulators of neuropeptide Y2 receptors
JP2011500778A (en) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ Pyridine and pyrazine derivatives-083
WO2009057827A1 (en) 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
TW200927115A (en) 2007-11-16 2009-07-01 Boehringer Ingelheim Int Aryl-and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
EP2072506A1 (en) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine or thiadiazolyloxyphenylamidine und its use as fungicide
CL2008003785A1 (en) 2007-12-21 2009-10-09 Du Pont Pyridazine derived compounds; herbicidal compositions comprising said compounds; and method of controlling the growth of unwanted vegetation.
EP2242483B1 (en) 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
DE102007061963A1 (en) 2007-12-21 2009-06-25 Merck Patent Gmbh pyridazinone derivatives
CN101903385B (en) 2007-12-21 2013-11-06 帕劳制药股份有限公司 4-aminopyrimidine derivatives as histamine H4 receptor antagonists
WO2009080534A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
AU2008340421B2 (en) 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CA2709514A1 (en) 2007-12-21 2009-07-02 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
AR069869A1 (en) 2007-12-21 2010-02-24 Exelixis Inc BENZOFIDE DERIVATIVES [3,2-D] PROTEINQUINASE INHIBITING PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND USES OF THE SAME IN THE TREATMENT OF CANCER.
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
PE20091339A1 (en) 2007-12-21 2009-09-26 Glaxo Group Ltd OXADIAZOLE DERIVATIVES WITH ACTIVITY ON S1P1 RECEPTORS
CN101537006B (en) 2008-03-18 2012-06-06 中国科学院上海药物研究所 Application of pyridazinone compounds in preparing antitumor drugs
DE102008019907A1 (en) 2008-04-21 2009-10-22 Merck Patent Gmbh pyridazinone derivatives
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (en) 2008-06-18 2009-12-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
EP2323994A1 (en) 2008-07-25 2011-05-25 Boehringer Ingelheim International GmbH Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
BRPI1013159A2 (en) 2009-03-30 2015-09-15 Sumitomo Chemical Co USE OF PYRIDAZINONE COMPOUND FOR ARTHROPOD PEST CONTROL
AR082590A1 (en) 2010-08-12 2012-12-19 Hoffmann La Roche INHIBITORS OF THE TIROSINA-QUINASA DE BRUTON

Also Published As

Publication number Publication date
TW201028409A (en) 2010-08-01
WO2010072295A1 (en) 2010-07-01
CL2011001278A1 (en) 2011-09-30
BRPI0923480A2 (en) 2016-08-09
IL213647A0 (en) 2011-07-31
JP2012513417A (en) 2012-06-14
DK2361250T3 (en) 2013-11-04
PL2361250T3 (en) 2014-01-31
KR101663335B1 (en) 2016-10-06
AR074686A1 (en) 2011-02-02
CN102264729B (en) 2014-03-05
NZ594172A (en) 2013-04-26
US8586599B2 (en) 2013-11-19
CA2748218C (en) 2017-08-29
JP5690741B2 (en) 2015-03-25
MX2011006682A (en) 2011-07-13
CN102264729A (en) 2011-11-30
BRPI0923480B8 (en) 2021-05-25
TWI448463B (en) 2014-08-11
UA103646C2 (en) 2013-11-11
EP2361250B1 (en) 2013-08-07
AU2009331990B2 (en) 2016-04-14
US20110257180A1 (en) 2011-10-20
ZA201105394B (en) 2012-03-28
AU2009331990A1 (en) 2011-08-11
CY1114659T1 (en) 2016-10-05
EA019320B1 (en) 2014-02-28
EA201100973A1 (en) 2012-01-30
MY160526A (en) 2017-03-15
BRPI0923480B1 (en) 2020-10-13
EP2361250A1 (en) 2011-08-31
PE20120016A1 (en) 2012-01-24
CA2748218A1 (en) 2010-07-01
CO6331435A2 (en) 2011-10-20
JP2015028093A (en) 2015-02-12
JP5860125B2 (en) 2016-02-16
SI2361250T1 (en) 2013-12-31
ES2434247T3 (en) 2013-12-16
SG172128A1 (en) 2011-07-28
SMT201300133B (en) 2014-03-07
IL213647A (en) 2013-11-28
HRP20130993T1 (en) 2013-11-22
HK1164837A1 (en) 2012-09-28
KR20110089462A (en) 2011-08-08
PT2361250E (en) 2013-11-11

Similar Documents

Publication Publication Date Title
ECSP11011248A (en) NEW POLYMORPHIC FORMS OF 3- (1- {3- [5- (1-METHYL-PIPERIDIN-4-ILMETOXI) -PIRIMIDIN-2-IL] -BENCIL} -6-OXO-1,6-DIHYDR CHLORIDE -PIRIDAZIN-3-IL) -BENZONITRILE AND ITS PREPARATION PROCESSES.
CO6612243A2 (en) Derivatives of [1.8] naphthyridine
CO6470876A2 (en) 3- [4- (7H-PIRROLO [2,3-D] PIRIMIDIN-4-IL) -1H-PIRAZOL-1-IL] OCTANO- OR HEPTANO-NITRILE AS JAK INHIBITORS.
CU24187B1 (en) SUBSTITUTED DERIVATIVES OF USEFUL IMIDAZOPIRIDAZINES FOR THE TREATMENT OR PROFILAXIS OF HYPERPROLIFERATIVE DISORDERS AND ANGIOGENESIS
CR20130280A (en) PIRROLOPIRIDINE AND PIRROLOPIRIMIDINE DERIVATIVES REPLACED WITH CYCLOBUTILO AS JAK INHIBITORS
CL2012003503A1 (en) Compounds derived from substituted morpholin pyrimidines, protein kinase atr inhibitors; Pharmaceutical composition, useful for the prevention or treatment of cancer tumors.
HUE061909T2 (en) Use of pyrazolo[1,5-a]pyrimidines as ATR kinase inhibitors for the treatment of cancer
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
MX353308B (en) Phosphorous derivatives as kinase inhibitors.
CR20140288A (en) BENZOTIENILO-PIRROLOTRIAZINAS DISUSTITUIDAS AND ITS USES
UY33587A (en) NEW COMPOUNDS AS SYK AND JAK QUINASE INHIBITORS
ECSP088906A (en) PIRAZOLO 1,5-a PYRIMIDINS
CO6280420A2 (en) 4-PIRAZOLIL-N-ARILPIRIMIDIN-2-AMINAS AND 4-PIRAZOLIL-N-HETEROARILPIRIMIDIN-2-AMINAS AS INHIBITORS OF JANUS KINASES
CL2011001972A1 (en) Compounds derived from fused pyrimidine, akt inhibitors; process of preparing said compounds and intermediates; intermediary compounds; pharmaceutical composition that includes them; pharmaceutical combination that understands them and their uses in the treatment of hyperproliferative diseases.
UY32529A (en) HETEROCYCLIC COMPOUNDS AND ITS USE AS INHIBITORS OF GLUCOGEN SYNTHEASE QUINASE 3
ECSP11011219A (en) NEW POLYMODIC FORMS OF DIHYDROGEN-PHOSPHATE 6- (1-METHYL-1H-PIRAZOL-4-IL) -2- {3- [5- (2-MORFOLIN-4-IL-ETOXI) -PIRIMIDIN-2-IL] -BENCIL} -2H-PIRIDAZIN-3-ONA AND PROCESSES FOR PREPARATION.
CL2009001112A1 (en) Cinnoline-3-carboxamide derived compounds, csf-1r kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment of cancer.
WO2012019192A3 (en) Cell-permeable molecules as growth factor receptor antagonists
BRPI0912970A2 (en) dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumors
NZ737572A (en) Intermediate compounds for the preparation of bipiperidine-2-one compounds
TH135036A (en) New polymorphic pattern of 6- (1- methyl -1H-pyrazol-4-il) -2- (3- (5- (2- morpholine-4-il-etoxy) - Pyrimidine-2-il) -benzyl) -2H-pyridazine-3-transfer Dihydrogen phosphate And the process of producing such crystals
NZ743260A (en) Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors
UY33553A (en) HETEROARILOS AND USES OF THE SAME